See more : Sanco Trans Limited (SANCTRN.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Psychemedics Corporation (PMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Psychemedics Corporation, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Resilux NV (RES.BR) Income Statement Analysis – Financial Results
- KSK Energy Ventures Limited (KSK.NS) Income Statement Analysis – Financial Results
- Jade Art Group Inc. (JADA) Income Statement Analysis – Financial Results
- Union Electric Company (UEPCN) Income Statement Analysis – Financial Results
- CNB Corporation (CNBZ) Income Statement Analysis – Financial Results
Psychemedics Corporation (PMD)
About Psychemedics Corporation
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine and Fentanyl. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Acton, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22.10M | 25.24M | 24.91M | 21.36M | 37.68M | 42.67M | 39.70M | 38.98M | 26.98M | 29.20M | 26.87M | 25.22M | 24.09M | 20.11M | 16.95M | 22.95M | 24.57M | 23.43M | 21.39M | 18.94M | 16.00M | 16.07M | 15.73M | 19.22M | 19.60M | 17.70M | 15.40M | 12.20M | 10.10M | 8.70M | 6.60M | 4.00M | 2.50M | 1.70M | 300.00K | 100.00K |
| Cost of Revenue | 13.69M | 15.95M | 14.65M | 16.47M | 21.23M | 22.06M | 19.88M | 17.53M | 14.26M | 14.07M | 11.48M | 10.97M | 9.62M | 8.07M | 7.35M | 9.60M | 9.89M | 9.37M | 8.81M | 8.49M | 7.63M | 7.02M | 7.82M | 8.90M | 7.20M | 6.50M | 5.40M | 4.50M | 4.20M | 3.30M | 2.40M | 1.60M | 1.40M | 1.00M | 1.30M | 300.00K |
| Gross Profit | 8.41M | 9.29M | 10.26M | 4.89M | 16.44M | 20.62M | 19.82M | 21.45M | 12.72M | 15.14M | 15.39M | 14.25M | 14.47M | 12.04M | 9.61M | 13.35M | 14.68M | 14.06M | 12.58M | 10.45M | 8.37M | 9.05M | 7.92M | 10.32M | 12.40M | 11.20M | 10.00M | 7.70M | 5.90M | 5.40M | 4.20M | 2.40M | 1.10M | 700.00K | -1.00M | -200.00K |
| Gross Profit Ratio | 38.07% | 36.81% | 41.21% | 22.87% | 43.64% | 48.32% | 49.93% | 55.03% | 47.14% | 51.83% | 57.29% | 56.50% | 60.08% | 59.88% | 56.68% | 58.17% | 59.74% | 60.00% | 58.80% | 55.17% | 52.33% | 56.32% | 50.32% | 53.72% | 63.27% | 63.28% | 64.94% | 63.11% | 58.42% | 62.07% | 63.64% | 60.00% | 44.00% | 41.18% | -333.33% | -200.00% |
| Research & Development | 1.14M | 1.33M | 1.13M | 1.28M | 1.57M | 1.55M | 1.36M | 1.42M | 1.63M | 1.35M | 825.10K | 825.52K | 607.41K | 481.43K | 467.44K | 474.62K | 489.01K | 444.53K | 335.77K | 329.42K | 305.68K | 358.10K | 608.19K | 475.70K | 500.00K | 500.00K | 400.00K | 400.00K | 400.00K | 400.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 7.19M | 5.86M | 6.13M | 6.10M | 7.22M | 6.43M | 5.64M | 4.97M | 4.56M | 4.47M | 4.16M | 3.95M | 3.95M | 4.20M | 3.60M | 4.52M | 7.05M | 6.05M | 5.91M | 5.79M | 6.13M | 6.76M | 6.98M | 7.42M | 7.10M | 6.40M | 5.90M | 4.40M | 3.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 3.00M | 3.19M | 2.80M | 3.58M | 4.66M | 5.03M | 4.67M | 4.96M | 5.05M | 4.63M | 4.70M | 4.54M | 4.12M | 2.95M | 2.96M | 3.65M | 12.50K | 0.00 | 0.00 | 0.00 | 2.82B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.19M | 9.05M | 8.93M | 9.67M | 11.88M | 11.46M | 10.31M | 9.93M | 9.61M | 9.10M | 8.86M | 8.49M | 8.06M | 7.15M | 6.56M | 8.17M | 7.05M | 6.05M | 5.91M | 5.79M | 6.13M | 6.76M | 6.98M | 7.42M | 7.10M | 6.40M | 5.90M | 4.40M | 3.70M | 2.80M | 2.90M | 2.70M | 2.30M | 2.60M | 0.00 | 1.70M |
| Other Expenses | 0.00 | 43.00K | -1.03M | -140.00K | 58.00K | 43.00K | 20.00K | -134.00K | -124.59K | -56.58K | 92.27K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.30M | 1.00M | 700.00K | 500.00K | 600.00K | 400.00K | 300.00K | 200.00K | 200.00K | 200.00K | 100.00K | 100.00K |
| Operating Expenses | 11.33M | 10.37M | 10.06M | 10.95M | 13.45M | 13.01M | 11.67M | 11.34M | 11.25M | 10.45M | 9.69M | 9.32M | 8.67M | 7.63M | 7.03M | 8.64M | 7.54M | 6.49M | 6.25M | 6.12M | 6.43M | 7.11M | 7.59M | 7.89M | 8.90M | 7.90M | 7.00M | 5.30M | 4.70M | 3.60M | 3.20M | 2.90M | 2.50M | 2.80M | 100.00K | 1.80M |
| Cost & Expenses | 25.02M | 26.32M | 24.70M | 27.43M | 34.68M | 35.06M | 31.54M | 28.87M | 25.50M | 24.52M | 21.16M | 20.29M | 18.29M | 15.69M | 14.37M | 18.24M | 17.43M | 15.86M | 15.06M | 14.61M | 14.06M | 14.13M | 15.41M | 16.79M | 16.10M | 14.40M | 12.40M | 9.80M | 8.90M | 6.90M | 5.60M | 4.50M | 3.90M | 3.80M | 1.40M | 2.10M |
| Interest Income | 0.00 | 0.00 | 49.00K | 75.00K | 134.00K | 149.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.89K | 5.35K | 23.09K | 45.32K | 308.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 49.00K | 75.00K | 59.00K | 106.00K | 0.00 | 134.00K | 124.59K | 56.58K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.67M | 3.32M | 3.69M | 3.63M | 2.91M | 3.06M | 2.81M | 2.29M | 1.73M | 1.05M | 872.17K | 586.97K | 370.02K | 284.91K | 336.80K | 331.39K | 347.13K | 287.44K | 408.97K | 533.59K | 871.99K | 1.14M | 1.27M | 1.28M | 1.30M | 1.00M | 700.00K | 500.00K | 600.00K | 400.00K | 300.00K | 200.00K | 200.00K | 200.00K | 100.00K | 100.00K |
| EBITDA | -251.00K | 2.23M | 3.90M | -2.44M | 5.91M | 7.61M | 10.96M | 12.40M | 2.75M | 5.49M | 6.58M | 5.52M | 6.17M | 4.70M | 2.92M | 5.04M | 7.49M | 7.85M | 6.74M | 4.86M | 2.81M | 3.08M | 1.59M | 3.71M | 4.80M | 4.30M | 3.70M | 2.90M | 1.80M | 2.20M | 1.30M | -300.00K | -1.20M | -1.90M | -1.00M | -400.00K |
| EBITDA Ratio | -1.14% | -4.29% | 0.84% | -28.40% | 7.96% | 17.83% | 20.55% | 25.94% | 5.45% | 16.06% | 21.24% | 19.57% | 25.61% | 23.37% | 15.24% | 21.95% | 30.47% | 33.51% | 31.48% | 25.62% | 17.57% | 18.31% | 10.11% | 16.88% | 24.49% | 20.90% | 20.78% | 20.49% | 13.86% | 22.99% | 19.70% | -10.00% | -48.00% | -111.76% | -333.33% | -2,000.00% |
| Operating Income | -2.92M | -1.08M | -3.48M | -6.07M | 84.00K | 7.65M | 8.16M | 10.11M | 1.47M | 4.69M | 5.71M | 4.94M | 5.80M | 4.41M | 2.58M | 4.71M | 7.14M | 7.56M | 6.33M | 4.33M | 1.94M | 1.94M | 323.19K | 2.43M | 3.50M | 3.30M | 3.00M | 2.40M | 1.20M | 1.80M | 1.00M | -500.00K | -1.40M | -2.10M | -1.10M | -2.00M |
| Operating Income Ratio | -13.22% | -4.29% | -13.97% | -28.40% | 0.22% | 17.93% | 20.55% | 25.94% | 5.45% | 16.06% | 21.24% | 19.57% | 24.08% | 21.95% | 15.24% | 20.51% | 29.06% | 32.29% | 29.58% | 22.87% | 12.12% | 12.05% | 2.05% | 12.64% | 17.86% | 18.64% | 19.48% | 19.67% | 11.88% | 20.69% | 15.15% | -12.50% | -56.00% | -123.53% | -366.67% | -2,000.00% |
| Total Other Income/Expenses | -517.00K | 43.00K | -1.03M | -140.00K | 58.00K | 43.00K | 20.00K | -134.00K | -124.00K | -57.00K | 92.27K | 1.89K | 5.35K | 23.09K | 45.32K | 308.03K | 416.65K | 294.04K | 122.20K | 47.73K | 41.13K | 178.70K | 125.33K | 461.64K | 400.00K | 600.00K | 600.00K | 400.00K | 500.00K | 100.00K | 0.00 | 100.00K | 0.00 | 0.00 | 0.00 | 500.00K |
| Income Before Tax | -3.44M | -1.04M | -821.00K | -6.21M | 3.06M | 7.65M | 8.18M | 9.98M | 1.35M | 4.63M | 5.80M | 4.94M | 5.81M | 4.44M | 2.63M | 5.01M | 7.56M | 7.86M | 6.45M | 4.38M | 1.98M | 2.11M | 448.53K | 2.89M | 3.90M | 3.90M | 3.60M | 2.80M | 1.70M | 1.90M | 0.00 | -400.00K | 0.00 | 0.00 | 0.00 | -1.90M |
| Income Before Tax Ratio | -15.56% | -4.12% | -3.30% | -29.05% | 8.11% | 17.93% | 20.60% | 25.59% | 4.99% | 15.86% | 21.58% | 19.58% | 24.10% | 22.07% | 15.51% | 21.85% | 30.75% | 33.54% | 30.15% | 23.12% | 12.37% | 13.16% | 2.85% | 15.04% | 19.90% | 22.03% | 23.38% | 22.95% | 16.83% | 21.84% | 0.00% | -10.00% | 0.00% | 0.00% | 0.00% | -1,900.00% |
| Income Tax Expense | 716.00K | 44.00K | -156.00K | -2.35M | 1.51M | 3.07M | 2.06M | 3.30M | -164.39K | 1.43M | 1.99M | 1.96M | 2.32M | 1.82M | 1.10M | 2.05M | 3.07M | 2.96M | 2.40M | 1.62M | 760.80K | 859.00K | 216.00K | 1.19M | 1.60M | 1.50M | 1.10M | 300.00K | 100.00K | 100.00K | 0.00 | -100.00K | 100.00K | 0.00 | -100.00K | -300.00K |
| Net Income | -4.15M | -1.08M | -665.00K | -3.86M | 1.54M | 4.58M | 6.12M | 6.68M | 1.51M | 3.21M | 3.81M | 2.98M | 3.49M | 2.61M | 1.53M | 2.97M | 4.48M | 4.90M | 4.05M | 2.76M | 1.22M | 1.26M | 232.53K | 1.70M | 2.30M | 2.40M | 2.50M | 2.50M | 1.60M | 1.80M | 1.00M | -500.00K | -1.50M | -2.10M | -1.00M | -1.80M |
| Net Income Ratio | -18.80% | -4.29% | -2.67% | -18.07% | 4.09% | 10.74% | 15.42% | 17.13% | 5.60% | 10.98% | 14.16% | 11.81% | 14.48% | 13.00% | 9.01% | 12.94% | 18.25% | 20.93% | 18.93% | 14.59% | 7.62% | 7.81% | 1.48% | 8.84% | 11.73% | 13.56% | 16.23% | 20.49% | 15.84% | 20.69% | 15.15% | -12.50% | -60.00% | -123.53% | -333.33% | -1,800.00% |
| EPS | -0.72 | -0.19 | -0.12 | -0.70 | 0.28 | 0.83 | 1.11 | 1.23 | 0.28 | 0.60 | 0.72 | 0.57 | 0.67 | 0.50 | 0.29 | 0.57 | 0.86 | 0.95 | 0.79 | 0.54 | 0.23 | 0.24 | 0.04 | 0.32 | 0.44 | 0.44 | 0.44 | 0.44 | 0.27 | 1.55 | 0.93 | -0.13 | -0.39 | -0.71 | -0.39 | -1.10 |
| EPS Diluted | -0.72 | -0.19 | -0.12 | -0.70 | 0.28 | 0.83 | 1.10 | 1.22 | 0.28 | 0.60 | 0.72 | 0.57 | 0.67 | 0.50 | 0.29 | 0.57 | 0.85 | 0.94 | 0.78 | 0.54 | 0.23 | 0.24 | 0.04 | 0.32 | 0.44 | 0.44 | 0.44 | 0.44 | 0.27 | 1.40 | 0.78 | -0.13 | -0.39 | -0.71 | -0.39 | -1.10 |
| Weighted Avg Shares Out | 5.74M | 5.63M | 5.55M | 5.52M | 5.51M | 5.51M | 5.49M | 5.45M | 5.41M | 5.36M | 5.30M | 5.26M | 5.23M | 5.21M | 5.19M | 5.22M | 5.21M | 5.17M | 5.16M | 5.13M | 5.19M | 5.26M | 5.29M | 5.31M | 5.46M | 5.55M | 5.49M | 5.54M | 5.85M | 5.02M | 3.87M | 3.87M | 3.82M | 2.94M | 2.60M | 1.63M |
| Weighted Avg Shares Out (Dil) | 5.74M | 5.63M | 5.55M | 5.52M | 5.53M | 5.52M | 5.56M | 5.48M | 5.41M | 5.38M | 5.32M | 5.27M | 5.24M | 5.23M | 5.20M | 5.25M | 5.30M | 5.24M | 5.17M | 5.13M | 5.20M | 5.28M | 5.34M | 5.37M | 5.51M | 5.65M | 5.64M | 5.54M | 5.85M | 5.02M | 3.87M | 3.87M | 3.82M | 2.94M | 2.60M | 1.63M |
Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance
ACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance.
Psychemedics Corporation Reports Third Quarter 2023 Financial Results
ACTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2023.
Unveiling the Future of Drug Testing: Psychemedics Introduces Advanced 5-Panel Drug Screen
Psychemedics debuts a 5-panel drug test replacing marijuana with fentanyl, the first hair drug test exclusively targeting the most dire workplace threats.
Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue Officer
ACTON, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the world's largest provider of hair testing for drugs of abuse, is pleased to announce the appointment of Shannon Shoemaker as its new Chief Revenue Officer. In this role, Shoemaker...
Psychemedics Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACTON, Mass., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's largest provider of hair testing for drugs of abuse, announced the grant of inducement awards to its newly appointed President and Chief Executive Officer, Brian Hullinger,...
Psychemedics Corporation Reports Second Quarter 2023 Financial Results
ACTON, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2023.
Psychemedics Corporation Announces CEO Succession Plan
Brian Hullinger Will Succeed Ray Kubacki as CEO Effective August 17, 2023 Mr. Hullinger Brings 30 Years of Leadership Experience and a Proven Track Record of Driving Growth ACTON, Mass.
Psychemedics: 21% Sales Growth But Net Loss, Takeover Possibility, Covid Recovery Play
21% YoY revenue growth in Q4, gross margins surge 1,000 bps YoY. EPS loss of $0.29 on higher legal costs and a one-time expense.
Small And Microcap Newsletter: DHT Holdings Financials Give It Time Until The Next Tanker Bull Market
In this week's newsletter, we look at a company in the middle of monetizing its major asset to see what is left after the deal closes. We also review a shipping company that has built a strong margin of safety.
Psychemedics: Q3 Revenues +29%, Margins Surge, Possible Corporate Actions Including Dividend
29% YoY revenue growth in Q3, margins surge.
Source: https://incomestatements.info
Category: Stock Reports